Sign In
Buy COCP
$1.06
+0.0100 (+0.95%)
At Close: Jun 03, 2026
BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to m
Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza
08:00am, Tuesday, 26'th May 2026
Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represen
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
08:00am, Friday, 15'th May 2026
BOTHELL, Wash., May 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipeline and business activities
BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its f
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988
10:03am, Thursday, 02'nd Apr 2026
The company said the FDA's Fast Track designation is intended to facilitate development and expedite regulatory review for drugs that treat serious conditions and address unmet medical needs.
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
08:00am, Thursday, 02'nd Apr 2026
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion i
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
08:00am, Tuesday, 31'st Mar 2026
Phase 1b norovirus challenge study is underway at Emory University School of Medicine CDI-988 is the first oral antiviral candidate being developed for norovirus treatment and prevention No approved t
Cocrystal Pharma (COCP) Expected to Announce Earnings on Monday
02:14am, Monday, 23'rd Mar 2026
Cocrystal Pharma (NASDAQ: COCP - Get Free Report) is anticipated to issue its results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.18) per sha
Cocrystal Pharma (NASDAQ:COCP) Shares Up 2% – Should You Buy?
02:13am, Tuesday, 10'th Mar 2026
Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report)'s stock price traded up 2% during mid-day trading on Monday. The stock traded as high as $1.0338 and last traded at $1.03. 48,239 shares changed
First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment
08:00am, Monday, 09'th Mar 2026
CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No appr
BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its d
Insider Buying: Cocrystal Pharma (NASDAQ:COCP) Director Buys $19,400.00 in Stock
05:18am, Saturday, 03'rd Jan 2026
Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) Director Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock in a transaction on Tuesday, December 30th. The stock was acquire
BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the approval from the Institutional Review Board (IRB) at Emory
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference
08:00am, Monday, 01'st Dec 2025
BOTHELL, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, CFO and co-CEO, will present a Company overv
Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
08:00am, Friday, 14'th Nov 2025
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026 Granted NIH SBIR award to advance in
